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Abstract
Protein silencing is often employed as a means to aid investigations in protein function and is increasingly desired as a thera-
peutic approach. Several types of protein silencing methodologies have been developed, including targeting the encoding 
genes, transcripts, the process of translation or the protein directly. Despite these advances, most silencing systems suffer 
from limitations. Silencing protein expression through genetic ablation, for example by CRISPR/Cas9 genome editing, is 
irreversible, time consuming and not always feasible. Similarly, RNA interference approaches warrant prolonged treatments, 
can lead to incomplete protein depletion and are often associated with off-target effects. Targeted proteolysis has the potential 
to overcome some of these limitations. The field of targeted proteolysis has witnessed the emergence of many methodologies 
aimed at targeting specific proteins for degradation in a spatio-temporal manner. In this review, we provide an appraisal of 
the different targeted proteolytic systems and discuss their applications in understanding protein function, as well as their 
potential in therapeutics.
Keywords Nanobody · Monobody · Ubiquitin · Proteasome · Auxin · Affinity-directed protein missile · VHL · CRBN · 
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Introduction
Understanding the inherent function of a protein is a cor-
nerstone in life sciences. Many biochemical and biophysical 
properties of proteins can be ascertained in vitro; however, 
a key drawback of these approaches is the absence of the 
cellular context. In cellulo research on the function of a pro-
tein of interest (POI) often relies on its deletion or depletion 
from cells to screen for changes in, for example, phenotype, 
signalling or gene expression patterns. Two current rou-
tine approaches used to achieve POI deletion or depletion 
are genome editing, for example by using CRISPR/Cas9-
mediated gene knockout, and RNA interference (RNAi), 
respectively.
With recent advances in CRISPR/Cas9 genome editing, 
targeted knockout of genes in cells, tissues and whole organ-
isms has been widely utilized to assess protein function. 
CRISPR/Cas9 is a bacterial and archaeal defence mechanism 
against viral infections, which acts to cleave foreign DNA 
or RNA from invading pathogens, thereby limiting infection 
[1]. Back in 2012, this system was adapted as a powerful 
genome editing tool [2] which could be utilized to either 
knockout a target gene, or introduce new DNA sequences 
into the genome in eukaryotic cells (Fig. 1, top). While 
CRISPR/Cas9 has since become an easy, cost-effective 
method for genome editing, it cannot be used for all targets, 
as single cell clones of essential gene knockouts will not 
survive the clonal selection process. Additionally, CRISPR/
Cas9 genome editing usually does not interfere with tran-
scription, but relies on the deletion of the start codon or 
introduction of nonsense mutations. However, mutagenesis 
by CRISPR can result in exon skipping, generating a differ-
ent start codon, resulting in truncations of the protein still 
being translated [3]. Even in the case of a true gene knock-
out, however, the time required for a single cell clone to 
propagate might be sufficient for cells to establish genetic 
compensation, thereby altering expression patterns of related 
proteins to make up for the loss of one protein [4]. Because 
gene knockouts are irreversible, the homeostatic changes in 
knockout cell clones might be very different from parental 
cells. Therefore, any interpretation of changes due to the 
loss of a POI relies on the ability to rescue phenotypes by 
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restoring the POI expression. This approach is not always 
feasible and often relies on the use of artificial and constitu-
tive promoters to drive protein expression.
RNAi-mediated depletion of a target POI transcript 
is a potential way to circumvent some of the problems of 
CRISPR/Cas9 genome editing highlighted above, as this 
technique is performed in a much shorter time frame than 
that required for a genetic knockout. In metazoan cells, RNAi 
approaches include short interfering RNAs (siRNAs), micro-
RNAs (miRNAs) and short hairpin RNAs (shRNA) [5]. In 
all of these cases, the RNAi machinery triggers the activa-
tion of the RNAi-induced silencing complex (RISC) and, 
depending on sequence complementarity, results in either 
degradation of the target RNA or inhibition of its transla-
tion (Fig. 1, middle) [6], leading to post-transcriptional gene 
silencing. While these methods enable the opportunity to 
target transcripts of essential genes, they ultimately rely on 
the turnover of the target protein for efficient reduction in 
target protein levels. For silencing of most POIs, RNAi is 
usually effective only after 48–72 h of treatment. However, 
for those proteins that have very slow turnover rates that sur-
pass this time frame [7], RNAi approaches will not yield the 
desired knockdown of target transcripts. Another common 
issue associated with RNAi appears to be off-target silenc-
ing of transcripts based on partial sequence complementa-
rity [8], despite great efforts going into the optimization of 
siRNA sequence design or delivery to minimize potential 
off-target effects [9].
An alternative approach, circumventing the challenges of 
protein silencing through genomic alterations or transcript 
inhibition, is the direct targeting of proteins for destruc-
tion. Targeted proteolysis is desirable both in therapeutic 
applications and in basic research. To date, such proteolytic 
approaches have relied on the cells’ built-in protein recycling 
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Fig. 1  Comparison of protein silencing tools and their advantages 
(PRO) and disadvantages (CON). Top: CRISPR/Cas9 genome editing 
results in mutations of target gene sequence, typically through dele-
tion of the start ATG codon, and introduction of early stop codons 
or frame shifts. While transcripts are still produced, translation is 
blocked. Middle: RNAi approaches result in cleavage of the mRNA 
transcripts. This in turn effectively blocks translation of the protein. 
Bottom: targeted proteolysis: While both transcription and translation 
remain unaffected, through mechanisms described for the different 
proteolytic methods, the target protein is directly marked for protea-
somal degradation
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centre, known as the ubiquitin–proteasome system (UPS). In 
short, proteins are marked for destruction through the cova-
lent attachment of the small protein ubiquitin onto primarily 
lysine residues on the target protein [10, 11]. The first step 
of the reaction is mediated by the E1 ubiquitin-activating 
enzyme that activates the ubiquitin monomer. Subsequently, 
the activated ubiquitin is passed on to the E2 ubiquitin-con-
jugating enzyme, before ultimately being attached to the 
target protein through the action of an E3 ubiquitin ligase. 
The ubiquitin monomers can be further ubiquitinated to form 
chains, with distinct chain types linked to specific biologi-
cal processes [12–14]. For example, and of relevance here, 
if ubiquitin molecules added to the target protein form a 
lysine 48-linked chain, the ubiquitinated protein is marked 
for proteasomal degradation [12, 13]. The proteasome itself 
is a cylindrical multimeric protein complex composed of 
a 20S core particle consisting of structural alpha subunits, 
as well as catalytic beta subunits that possess the protease 
activity [15–17]. At either end of the 20S core particle is 
a 19S regulatory particle. This regulatory component acts 
as a gatekeeper to regulate entry of target proteins into the 
catalytic 20S core, thereby controlling proteolysis [15–17].
The possibility of using the native UPS to selectively 
degrade POIs for which genes cannot be knocked out 
genetically or silenced by RNAi is an attractive alternative 
approach (Fig. 1, bottom). The field of targeted proteolysis 
is beginning to rapidly gather pace and provides many ways 
to remove target proteins independently of genomic or tran-
scriptional modulation. All targeted proteolysis approaches 
rely on the concept of recruiting the POI to an E3 ligase for 
ubiquitination and subsequent degradation. The first step 
of targeted proteolysis requires a robust system for target 
recognition. This can be achieved through a POI-specific 
high-affinity binder, e.g. a camelid derived nanobody [18, 
19] or a synthetic small molecule [20]. In turn, these POI-
targeting elements can be interlinked with either the proteo-
lytic UPS-inducing E3 ligase element (often an E3 ligase, its 
catalytic domain or a substrate receptor of an E3 ligase com-
plex) or with a small molecule targeting the E3 ligase [20, 
21]. Alternatively, degradation of the POI can be achieved 
through fusion of the POI to a degron sequence [22, 23]. In 
terms of POI-targeting elements, the advances in both small 
molecules and engineered polypeptides means that many 
approaches now exist for targeted proteolysis of intracellular 
POIs. In the following sections, we present several of these 
systems, highlighting their benefits and limitations.
Auxin‑inducible degron (AiD)
Plant cell signalling relies on phytohormones like auxin 
(AUX). Upon exposure to hormones of the auxin family, 
such as indole-3-acetic acid (IAA), the AUX/IAA family 
of transcriptional repressor proteins are rapidly degraded 
through a specific form of the SCF (SKP–cullin–F-Box)-
RING E3 Ligase system [24, 25]. Auxin hormones bind to 
the F-box transport inhibitor response 1 (TIR1) protein and, 
in doing so, promote the association between the SCF-TIR1 
E3 ligase complex with AUX/IAA transcriptional repres-
sors, ultimately leading to the ubiquitination and degrada-
tion of the AUX/IAA transcriptional repressors [24, 25]. 
Whilst other eukaryotes lack this auxin-inducible response, 
the SCF degradation pathway is conserved, thereby raising 
the tantalizing possibility that the auxin-inducible degrada-
tion pathway could be transferred into other eukaryotic cells. 
The Kanemaki lab demonstrated this possibility with rapid, 
reversible degradation of essential POIs in cell lines derived 
from various organisms including chicken, mouse, yeast, and 
humans [24]. They achieved this through fusion of an IAA17 
degron sequence (AID) to the POI and overexpression of 
TIR1 in target cells. Rapid POI degradation was observed 
following IAA treatment (Fig. 2a) [24]. They named this 
system the auxin-inducible degron [(AiD) with a lower-
case i to differentiate it from the AID degron sequence]. As 
it is generally believed that auxin is only active in plants, 
the off-target effects of auxin treatment are thought to be 
minimal. However, IAA oxidation through the action of 
eukaryotic peroxidases has been reported to be toxic at high 
doses [26], highlighting the need to test auxin sensitivity 
in the target cell line before utilizing this system. Ensuring 
there are no off-target effects of auxin in cells is critical, as 
relatively large amounts of IAA are required to induce POI 
degradation in cells [21, 24]. Current efforts in engineer-
ing and improving this system resulted in a higher-affinity 
auxin–TIR1 pair [27]. Future efforts aimed at implementing 
this “super strong” auxin–TIR1 into the AiD system may 
allow for lower drug treatments and further improve degra-
dation kinetics.
One of the key limitations of the AiD system is that it 
cannot be used to explore the effects of endogenous POI 
degradation without first inserting the IAA degron sequence 
at the POI locus. This has not been such an impediment in 
yeast, with demonstrations of robust and rapid AID-mutant 
generation [24]. Furthermore, as the AiD system does not 
require temperature modulation in yeast, in contrast to that 
required for temperature-sensitive degrons [28], it bypasses 
any off-target effects associated with the temperature adjust-
ment process. However, in metazoan cells the AiD system 
is more challenging to integrate, owing to the much less 
efficient homologous recombination compared to yeast.
With advances in CRISPR/Cas9 gene editing technolo-
gies, the AID degron sequence was successfully knocked 
into the genes encoding the cohesin and cytoplasmic dynein 
proteins in human colorectal cancer HCT116 cells. Follow-
ing TIR1 over-expression, IAA-responsive cohesin and 
dynein degradation were demonstrated [21]. Similar results 
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were also observed in mouse embryonic fibroblasts [21]. 
Whilst AiD presents a powerful tool to achieve POI degra-
dation in cells [21, 24], inserting a non-fluorescent AID tag 
homozygously into the POI locus by genome editing still 
remains a huge challenge. A recent study sought to over-
come this by tagging POIs with green fluorescent protein 
(GFP) and modifying the AiD system with an AID–anti-
GFP nanobody fusion. In this case, endogenously GFP-
tagged proteins in both human cells and zebrafish could be 
degraded in an auxin-inducible manner, when co-expressing 
the AID–anti-GFP nanobody fusion as well as TIR1 [29]. 
With any AiD system, potential off-target effects of over-
expressing the TIR1 protein in non-plant cells need to be 
delineated.
Conditionally‑stable FKBP12 and UnaG tag 
degrons
Some recent proteolytic advances have centred around 
the FKBP12–rapamycin–mTORC1 complex. Rapamycin, 
a highly-studied compound originally isolated from soil 
samples on Easter Island (Rapa Nui) [30], exerts its bio-
logical effects through simultaneously binding FKBP12 
and the FRB domain of mTOR, and subsequently inhib-
iting the master protein kinase complex mTORC1. Given 
rapamycin’s propensity to bind the FRB domain of mTOR, 
researchers employed a “bump-and-hole” strategy to gener-
ate rapamycin-like molecules that bind poorly to the wild-
type FRB domain of mTOR, but maintain strong binding 
against an engineered form of the FRB domain. For exam-
ple, the rapamycin-like molecule MaRap was found to bind 
poorly to wild-type FRB, but very strongly to a mutant of 
FRB (FRB*) [31], and fusion of this mutant to the kinase 
GSK-3β resulted in conditional extranuclear localization of 
GSK-3β [23, 32]. Additionally, in the absence of the MaRap 
ligand, this FRB*–GSK-3β fusion protein was much less 
stable than the wild-type FRB–GSK-3β fusion [23, 32]. This 
instability of the FRB*–GSK-3β fusion protein could be res-
cued upon MaRap treatment [32]. Thus, the idea that the 
FKBP12–rapamycin–FRB complex could be exploited for 
conditionally stable fusion proteins was born [23].
This concept was improved by creating a system that 
would allow inducible control of protein stability, by fusing 
mutants of the FKBP12 protein that mediate constitutive and 
rapid degradation following their expression in mammalian 
cells [23]. Following administration of a small molecule, 
Shld1, which binds the mutant FKBP12, the fusion protein 
is stabilized and therefore free to perform its biological 
role(s) (Fig. 2b) [23]. This Shld1-dependent stability was 
demonstrated in various cell lines, including those derived 
from humans [23], which opens up the possibility of using 
this system endogenously through CRISPR/Cas9 mediated 
gene editing of the POI. While this “drug-on” approach is 
(B) Shld/UnaG
POI
FKBP12m
/UnaG
POI
FKBP12m
/UnaG
Shld Ligand
/ BR
(C) SMASh Tag
POI NS3/4 POI NS3/4
Asunaprevir
POI NS3/4
(A) AiD
+
+ TIR1
TIR1
RBX1
U
SKP1
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POIIAA17
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Fig. 2  An overview of the proteolytic approaches using degrons. a 
Auxin-inducible degron (AiD): the POI is fused to an IAA17 degron. 
Expression of TIR1 and addition of auxin (IAA) results in the recruit-
ment of the IAA17-fused POI to TIR1, which in turn is recruited to 
the SKP1–Cul1–RBX1 complex, resulting in POI ubiquitination by 
RBX1. b Shld and UnaG degrons: in the absence of the stabilizing 
Shld ligand or bilirubin (BR), the POI is degraded when fused to the 
destabilizing FKBP12 or UnaG mutants, respectively. Addition of the 
respective compound stabilizes the fusion protein. c SMASh-Tag: the 
POI is fused to NS3/4 through an NS3 cleavage site. NS3 is cleaved 
from the POI and degraded, while the native POI is stable (right 
arrow). Upon addition of the NS3 inhibitor asunaprevir, NS3 cleavage 
is inhibited and the entire fusion protein is degraded (down arrow)
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reversible and tuneable, it requires chronic treatment with 
the Shld1 ligand to rescue the POI levels [23]. As such, this 
system provides a great strategy to analyse constitutively 
active enzymes, where Shld1-induced stabilization would 
trigger the experimental condition, rather than inhibiting it 
[23]. Despite the potential caveats of these drug-on methods, 
the applicability of this research is far reaching and has also 
formed the basis for subsequent attempts aimed at generating 
other effective proteolytic systems, such as the dTAG system 
for POI degradation which will be discussed later.
Another type of degron that can be stabilized upon the 
addition of a ligand has been engineered recently after the 
discovery of a new fluorescent protein from eel muscles. 
This protein, termed UnaG (Unagi eel green fluorescent 
protein), takes on a β-barrel shape which is capped by two 
α-helices. Fluorescence, with maximal absorption at 498 nm 
and maximal emission at 527 nm, requires bilirubin (BR) 
as a cofactor, placing it within the barrel structure of UnaG 
[33]. Random mutagenesis and screening of UnaG yielded a 
two amino acid substitution mutant (A36V, R136G), which 
acts as a destabilizing degron on fusion proteins in the 
absence of BR (tested on mCherry, proteasome interactors 
zfand2a and zfand2b, ubiquitin conjugating enzyme ube2n 
and the cell cycle regulator p21) (Fig. 2b) [22]. Notably, 
fusion of the UnaG degron to either terminus elicited degra-
dation of the fusion proteins by the 26S proteasome, and this 
degradation could be halted by BR treatment [22]. Studies 
on the kinetics of UnaG-mediated degradation have shown 
that fusion proteins were completely degraded 4 h after 
removal of BR from the growth medium. Additionally, the 
system’s mechanism exhibited dose-dependent degradation 
of fusion proteins [22]. With a molecular weight of roughly 
15 kDa, UnaG is only half the size of GFP, providing the 
advantage of a much smaller tag size when fused to target 
proteins, thereby reducing the potential unwanted effects that 
large tags can have on POIs.
SMASh‑tag degron
An alternative degron for controlled target protein deg-
radation utilizes part of the hepatitis C virus (HCV) non-
structural protein 3 (NS3) protease [34]. From the HCV 
transcript, one continuous protein is expressed, which is 
partially self-cleaved into the respective proteins by pro-
teases, including NS3 [35]. This property of NS3 has been 
utilized for other molecular and cellular tools previously 
[36], where fusion of the NS3 protease domain to NS4 (a 
cofactor for NS3) acted as a destabilizing degron [34, 36]. 
The exact mechanism of how this degron works has not yet 
been elucidated. However, the authors surmised that deletion 
of the cleavage site, between the NS3 protease domain and 
NS4, induces the degron-like function, as NS4 needs a free 
N-terminus for ER membrane integration. With the terminus 
being blocked by NS3, NS4 presumably retains degron-like 
properties [34].
Fused to either the N- or C-terminus of a POI, and con-
nected by an NS3 cleavage site, the degron continuously 
removes itself from the fusion protein, leaving the POI 
untagged within the cell (Fig. 2c). Upon treatment with 
specific protease inhibitors, like asunaprevir, which target 
the NS3 active site, the degron remains attached to the target 
protein leading to rapid POI degradation. Control over this 
system through the use of small molecules led to the name 
SMASh-tag (small molecule-assisted shutoff) [34]. Fusion 
of a SMASh-tag to either terminus of target proteins exhibits 
a degron-like function, and protein stability is tuneable with 
asunaprevir doses ranging from 0.15 nM (slightly reduced 
levels) to 1.5 µM (undetectable).
SMASh-tag provides an additional advantage on the 
study of protein half-life or degradation, as addition of asu-
naprevir only affects newly synthesized proteins and only 
those proteins tagged with the SMASh tag. Therefore, deg-
radation of the previously generated pool of the SMASh-
tagged target protein can be monitored without affecting 
any other proteins, which is not the case for conventional 
methods like cycloheximide treatment for ribosomal inhibi-
tion. No adverse effects on cell growth induced by asunap-
revir were reported [34]. Additionally, in combination with 
CRISPR/Cas9 technology, this method might prove to be 
very powerful in studying essential proteins.
TRIM away
TRIM21 belongs to the family of tripartite motif (TRIM) 
proteins, which are involved in various cellular processes, 
including antiviral responses [37]. TRIM proteins consist 
of a RING-box, which mediates the E3 ligase activity, a 
B-box and a coiled-coil domain [38]. Additionally, TRIM 
proteins contain a C-terminal PRYSPRY domain, which is 
thought to confer target specificity for the different TRIM 
members [38]. The TRIM-21 PRYSPRY domain interacts 
with the constant  Fc region of IgG antibodies with affin-
ity in the low nanomolar range, with a TRIM21:Fc ratio 
of 2:1 [38]. Uncharacteristically for  Fc receptors, TRIM21 
is localized in the cytosol, which in part explains its func-
tion in conferring intracellular immunity against viruses. 
Antibodies bound to viruses are co-endocytosed, leading 
to recognition by TRIM21, and subsequent autoubiquitina-
tion and degradation of the virus–antibody–TRIM21 com-
plex [39]. The Schuh research group developed a targeted 
proteolytic system, called TRIM-away, by exploiting this 
unique function of TRIM21. Following microinjection of a 
target-specific antibody, the POI is recognized by TRIM21, 
ubiquitinated and rapidly degraded (Fig. 3a) [40]. Using 
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a GFP-specific antibody for microinjection into TRIM21 
expressing cells, GFP levels were depleted with an apparent 
half-life of roughly 16 min [40]. The system could also be 
applied to primary cells, in which achieving protein silenc-
ing with RNAi or CRISPR/Cas9 is difficult. TRIM21 was 
able to target all accessible cellular proteins, although for 
nuclear-localized proteins, a target-specific nanobody has 
to be fused to  Fc fragments due to the full-length antibody 
being too large to pass through the nuclear pore complex. As 
shown by targeting huntingtin, TRIM-Away was also able to 
distinguish between wild-type and mutant proteins, depend-
ing on the specificity of the delivered antibody [40].
The power of TRIM-away was also shown by its ability 
to target and degrade Rec8 in mouse oocytes within min-
utes [40]. Rec8 is a meiosis-specific component of the cohe-
sion complex, required for tethering of sister chromatids in 
oocytes throughout the entire meiotic process. As such, Rec8 
does not turnover and is thought to have a half-life of several 
years in humans [7]. RNAi approaches lack the persistence 
to affect Rec8 protein levels, while CRISPR is not a viable 
option due to Rec8 being an essential gene.
TRIM-away was also able to impact signalling pathways 
downstream of target protein degradation. The longevity of 
TRIM-away efficacy was assessed to be roughly 3–4 days. 
However, this was dependent on the levels of target protein 
within cells, the amount of antibody being applied and the 
amount of TRIM21 within cells. To widen the applicability 
of the system beyond single cell analysis, the authors devel-
oped a bulk cell approach by using electroporation, show-
ing specific effects on signalling pathways like ERK1 or 
mTOR [40]. This approach additionally allows for co-elec-
troporation of TRIM21, omitting the stable overexpression 
lines needed previously. Alternatively, cell lines inherently 
expressing high amounts of TRIM21 can be used without 
co-electroporation or microinjection of TRIM21, facilitating 
the use of the system [40]. However, getting large amounts 
of pure and highly selective IgG antibodies into target cells 
is not only challenging, but extremely costly and therefore 
makes TRIM-away not as feasible as other proteolytic meth-
ods, especially when considering large-scale applications.
(A) TRIM Away
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TRIM21
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GFP
RBX1
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E3 
(complex)
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Fig. 3  An overview of the targeted proteolytic approaches using high-
affinity binders. a TRIM-away: the  FC region of POI-specific antibod-
ies, once injected into cells, is recognized by TRIM21, while the  Fab 
binds the POI. TRIM21 marks the POI for degradation through ubiq-
uitination. b AdPROM/DeGradFP/ZIF1: a cullin substrate receptor is 
fused to a target-specific or GFP-specific nanobody and expressed in 
cells. While the nanobody (nb) recognizes the POI/GFP, the receptor 
is recruited to the cullin–RBX–adaptor complex. Presentation of the 
POI to RBX1 results in ubiquitination and degradation of the POI. 
AdPROM and ZIF1 utilize the CUL2 system with EloB/C as adap-
tors, while employing VHL and ZIF1 as substrate receptors, respec-
tively. DeGradFP works with the CUL1 system, using SKP1 as an 
adaptor, and Slmb F-box as the substrate receptor. c Hydrophobic 
tagging: a synthetic molecule with a POI-binding moiety binds to 
the target protein. The fused hydrophobic adamantyl group leads to 
ubiquitination and degradation of the POI, presumably through the 
recruitment of the molecular chaperone Hsp70 and its co-chaperone, 
the E3 ligase CHIP. d PROTAC/SNIPER: a synthetic molecule with 
two warheads interacts with an E3 ligase on one end and a protein of 
interest on the other. Spatial proximity allows for ubiquitination of the 
POI which is subsequently degraded
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Affinity‑directed PROtein Missile system 
(AdPROM)
Recent data from our own laboratory described a novel and 
efficient proteolytic system that combines the endogenous 
cullin 2 (CUL2) CRL machinery, with high-affinity poly-
peptide binders for target protein recognition [18, 19]. We 
called this approach the Affinity-directed PROtein Missile 
(AdPROM) system. AdPROM works by first expressing the 
Von Hippel Lindau (VHL) protein, the substrate receptor 
for CUL2 [41], fused to a polypeptide binder that recog-
nizes a particular POI, in cells (Fig. 3b). We have used both 
camelid-derived VHH domain nanobodies and synthetic 
binders that use the human fibronectin type III domain as 
a backbone—so-called monobodies [42]—for this purpose. 
Such small polypeptide binders are ideal for intracellular 
expression, as they do not require complex folding or disul-
phide bridge formation, unlike conventional antibodies. 
Upon successful expression in cells, the VHL–nanobody/
monobody fusion protein binds the protein of interest and 
recruits it to the endogenous CUL2 machinery through the 
association of VHL with the elongin B and C adaptor pro-
teins [41, 43, 44]. Every cullin E3 ligase complex possesses 
a substrate receptor such as VHL, adaptor protein(s), a cullin 
and an RBX E3 ligase. Once the substrate receptor binds and 
recruits the substrate to the cullin complex, the substrate 
is in a prime position for RBX1/2-mediated ubiquitina-
tion [44, 45]. Cullins themselves are regulated by the post-
translational modification of NEDDylation, which serves to 
attach the small ubiquitin-like modifier NEDD8 onto lysine 
residues of the cullin, resulting in conformational changes 
required for optimal substrate ubiquitination [43, 46, 47]. 
With regard to the AdPROM system, the target POI, once 
recruited to the CUL2 complex, is ubiquitinated by RBX1 
and marked for destruction through the proteasome [18, 19].
By fusing VHL with the VHH domain nanobodies rec-
ognizing the inflammasomal protein ASC [48], or by fus-
ing VHL to either of the two monobodies that specifically 
bind the tyrosine phosphatase SHP2 [42], we showed robust 
degradation of endogenous ASC and SHP2 proteins, respec-
tively, in a whole host of human cancer cell lines [19]. These 
findings demonstrate that if a POI-targeting nanobody or 
polypeptide binder is available, the AdPROM system can 
be applied in any cell line to target POI degradation rapidly. 
Alternatively, for POIs for which the binding nanobodies/
monobodies do not yet exist, we generated GFP-tagged 
knockin POIs through CRISPR/Cas9 gene editing technol-
ogy, and utilized nanobodies recognizing GFP fused with 
VHL to induce degradation of endogenous GFP-tagged 
PAWS1 and VPS34 [18]. Excitingly, targeted degrada-
tion of GFP-VPS34 also led to the degradation of endog-
enous UVRAG, a protein which forms a stable complex 
with VPS34 [18]. As expected, the degradation of VPS34 
by AdPROM resulted in reduction in levels of endosomal 
phosphatidylinositol (3,4,5)-trisphosphate [18]. The targeted 
proteolysis by AdPROM is dependent on both proteasomal 
activity and cullin NEDDylation [18, 19]. Crucially, despite 
VHL being the substrate adaptor for endogenous hypoxia-
inducible factor 1α (HIF1α) [49], expression of AdPROM 
does not appear to interfere with hypoxia signalling, as evi-
denced by no detectable stabilization of HIF1α in AdPROM-
expressing cells [18, 19]. That being said, there may be other 
endogenous VHL targets and functions that have not yet 
been identified, and the impact of the AdPROM system on 
these and downstream biology needs to be tested further. 
AdPROM has not yet been applied for POI degradation in 
whole organisms.
DeGradFP and ZIF1 proteolytic systems
Similar to AdPROM, other E3 ligase systems have been 
combined with nanobodies recognizing GFP (GFPnb) to 
induce degradation of endogenously GFP-tagged POIs in 
intact organisms. One such approach, named deGradFP, 
utilized a fusion of an anti-GFP nanobody with the F-box 
domain from the Drosophila melanogaster Slmb protein, 
which is a substrate receptor component of the SCF E3 
ligase complex, and demonstrated efficient degradation of 
GFP-tagged proteins in D. melanogaster (Fig. 3b) [50, 51]. 
Similarly, another system harnesses the Caenorhabditis ele-
gans SOCS/CUL2 CRL complex for targeted degradation of 
proteins. The C. elegans SOCS-Box protein ZIF1 recruits 
proteins containing a 36 amino acid ZF1 motif and targets 
them for degradation [52]. By tagging POIs with such a ZF1 
motif, it is possible to recruit and degrade them via endog-
enous CRL machinery [52]. However, some disadvantages 
with this system are that ZIF1 itself is regulated in different 
stages of development [53] and POI degradation will com-
pete with endogenous substrates. More recently, the ZIF1 
system was also adapted to create a deGradFP system [54]. 
The ZIF1 protein was fused to a GFP nanobody (GFPnb) and 
expressed in C. elegans [50]. In combination with CRISPR/
Cas9 gene editing technology, it was demonstrated that the 
ZIF1–GFPnb polypeptide recruits and degrades GFP-tagged 
knockin POIs in vivo (Fig. 3b) [50]. These approaches show-
case the ability to degrade GFP-tagged POIs in an intact 
organism, and provide further merit for the applicabil-
ity of nanobody-based high-affinity binders in proteolytic 
biotechnology.
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Hydrophobic tagging (HyT)
Cells have developed an elaborate surveillance mechanism 
to help and maintain proteins in their proper folding state. 
Unfolded proteins are bound by molecular chaperones, 
which prevent their aggregation and help them regain their 
original folding [55]. However, molecular chaperones Hsp70 
and Hsp90 can also recruit the co-chaperone E3 ligase CHIP 
(C-terminus of Hsp70 interacting protein), which leads to 
ubiquitination and degradation of the chaperone-bound cli-
ent proteins [56–59]. To utilize this surveillance system for 
targeted proteolysis, the Crews lab created a small molecule 
with a POI-binding moiety coupled to a hydrophobic group 
for permanent chaperone binding (Fig. 3c). As a proof of 
principle, a HALO-tag reactive linker was joined with a 
hydrophobic adamantyl group. Treatment of cells express-
ing GFP-HALO with this compound (HyT13) resulted in 
efficient degradation (50% in 8 h at 1 µM), without notable 
toxicity even at concentrations up to 20 µM [56]. Remark-
ably, HALO-tagged fusions of transmembrane proteins with 
differing amounts of membrane spanning helices could be 
degraded by this system as well [56].
In an attempt to make the system more applicable and 
remove the need to create HALO-fusions, the HALO reac-
tive linker was exchanged for the Alzheimer’s disease-related 
protein Tau-interacting peptide (the C-terminal region of 
tubulin). This induced efficient degradation of Tau [60]. A 
similar result was achieved when the HALO reactive linker 
was switched with a high-affinity agonist for the androgen 
receptor, RU59063 [57], or with a newly developed inhibitor 
against the EGFR tyrosine kinase HER3, TX1-85-1 [61]. In 
all three cases, the high-affinity binders were linked to the 
hydrophobic adamantyl group. However, an exact mecha-
nistic explanation regarding this system, and any off-target 
effects resulting from potential perturbations of the unfolded 
protein response pathways, remains to be delineated.
PROteolysis‑TArgeting Chimeras (PROTACs)
Unlike most of the POI degradation systems described thus 
far, PROteolysis-TArgeting Chimeras (PROTACs) against 
endogenous POIs do not rely on prior genetic modification 
of the target gene. They are small bivalent molecules that 
simultaneously bind to the POI and an E3 ligase compo-
nent, ultimately leading to POI ubiquitination and degrada-
tion (Fig. 3d). The first PROTAC described consisted of an 
ovalicin headgroup that bound methionine-aminopeptidase 
2 (MetAP-2) linked to an IκBα derived peptide headgroup 
that bound the Skp1–cullin–F-Box (SCF) complex [62]. This 
molecule efficiently degraded MetAP-2 in Xenopus oocyte 
extracts, however it was not cell permeable [62]. Since then 
great efforts have gone into developing PROTACs that can 
traverse the cell membrane and target different E3-ligases 
and target proteins. Some of these PROTACs will be 
explored below.
MDM2‑based PROTACs
Mouse double minute 2 homolog (MDM2) is an oncopro-
tein with E3 ligase activity that targets the tumour suppres-
sor p53 for ubiquitination. MDM2 binds the p53 transac-
tivation domain, leading to the inhibition of p53 function, 
nuclear export and degradation under physiological condi-
tions. Upon cell stress, this interaction is disrupted lead-
ing to increased levels of active, nuclear-localized p53. 
However, MDM2 is one of the most upregulated E3 ligases 
in cancer, leading to constant removal of p53 [63–65]. To 
utilize MDM2 for the PROTAC system, the discovery of 
nutlins, small molecules that bind MDM2 at the p53 inter-
action interface, was a crucial step [66]. In an initial PRO-
TAC approach, the nutlin headgroup was combined with a 
selective androgen receptor modulator (SARM) moiety, and 
androgen receptor degradation was observed in a transient 
overexpression system [67]. Recently, a potent PROTAC has 
been developed that connects the MDM2-binder idasanutlin 
and the bromodomain containing protein 4 (BRD4) inhibitor 
JQ1. This PROTAC, A1874, degraded BRD4 almost com-
pletely in HCT116 cells at 100 nM within 24 h. Additionally, 
PROTAC treatment led to the stabilization of p53 and had an 
antiproliferative effect that was synergistic when compared 
to treatments with either inhibitor alone [68].
Cereblon (CRBN)‑based PROTACs
CRBN is a substrate recognition unit  of the 
CUL4–RBX1–DDB1 E3 ligase complex [69]. CRBN was 
shown to bind the drug thalidomide in its substrate bind-
ing pocket, thereby creating a new surface to recruit other 
proteins for ubiquitination and degradation, such as the tran-
scription factors Ikaros and Aiolos (IKZF1 and 3, respec-
tively) or the kinase CK1α [70–72]. However, thalidomide 
displaces endogenous CRBN substrates, such as the tran-
scription factor MEIS2 which is involved in embryonic 
development, perhaps explaining its teratogenic effects in 
pregnant women [69, 73–75]. Nevertheless, thalidomide and 
its derivatives, e.g. lenalidomide and pomalidomide, have 
been used for a newfound purpose in their immunomodu-
latory imide drug (IMiD) function and are applied in the 
treatment of several diseases, including erythema nodosum 
leprosum (ENL), multiple myeloma, myelodysplastic syn-
drome (MDS), systemic lupus erythematosus and inflamma-
tory bowel disease [75, 76].
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The compound CC-885 was recently added to the avail-
able pool of CRBN modulators. While maintaining the bind-
ing and degradation capability for IKZF1, CC-885 targeted 
GSPT1, a translation termination factor, for degradation. 
Notably, other available IMiDs did not have an effect on 
GSPT1 protein stability [77]. Structural analysis revealed the 
minimal requirement for IMiD targets to participate in the 
CRBN–IMiD interaction to be a surface-exposed turn, con-
taining a precisely positioned glycine residue [77, 78]. Addi-
tional interactions occur via hydrogen bonding of the sur-
rounding backbone. However, target-specific docking sites 
can be presented by the thalidomide derivative, as is the case 
with CC-885 and GSPT1 [77], as well as pomalidomide and 
the zinc finger proteins IKZF1 or ZNF692 [78]. A proteomic 
approach has also shown that a large subset of zinc finger 
proteins, in particular those containing  Cys2-His2 (C2H2) 
zinc finger domains that exhibit the specific glycine contain-
ing turn structure, can be degraded by IMiD-bound CRBN. 
Additionally, different IMiDs have been shown to induce the 
degradation of distinct Zn-finger proteins, which is attrib-
uted to steric and structural properties of the targets, and the 
CRBN–IMiD surface [78]. As such, the CRBN–IMiD-target 
interaction is not dictated by a specified sequence, but rather 
a structural motif.
While IMiDs undoubtedly provide a useful therapeutic 
approach for different diseases, their use in the context of 
targeted protein degradation is currently limited, as they 
would have to be painstakingly optimized. Nevertheless, tha-
lidomide and its derivatives provide a valuable warhead for 
the development of CRBN targeting PROTACs. Recently, 
the anaplastic lymphoma kinase (ALK) was degraded by 
two PROTACs based on a pomalidomide warhead target-
ing CRBN linked with either LDK378 (ceritinib) [79, 80] 
or TAE684 [79] targeting ALK. Both PROTACs were able 
to reduce downstream signalling and proliferation of ALK-
driven cell lines by degrading ALK [79, 80]. However, 
both PROTACs retained their inherent off-target binding of 
Aurora kinase A, as it too was degraded [79].
Another example of efficient utilization of CRBN for 
protein degradation was achieved with BRD4. The scaffold 
protein for transcriptional elongation factor P-TEFb [81] 
preferentially binds upstream of several oncogenes such as 
c-myc as so-called super-enhancers [82]. While protein–pro-
tein interactions of BRD4 can be inhibited by OTX015 or 
JQ1, which lead to suppressed levels of c-myc, the inhibi-
tory effect is quickly alleviated once the inhibitor is removed 
from cells [83, 84]. PROTACs consisting of pomalidomide 
and OTX015 [84] or JQ1 [85] resulted in robust BRD4 deg-
radation when used at low nanomolar concentrations [84, 
85]. Concomitantly, c-Myc levels were strongly depleted, 
and this depletion lasted longer after washout of the PRO-
TAC than after inhibitor treatment [84].
An important point to keep in mind when working on tar-
geted protein degradation is the compatibility of the desired 
target protein to be degraded, and the E3 ligase to be used, 
as exemplified by another PROTAC target of CRBN. In a 
dual approach, tyrosine kinase inhibitors targeting the onco-
genic fusion protein BCR–Abl, i.e. bosutinib or dasatinib, 
were either incorporated into a PROTAC targeting CRBN, 
or VHL. While binding of the PROTACs to BCR–Abl still 
inhibited downstream signalling, protein levels remained 
unchanged with any of the tested VHL-PROTACs. Inter-
estingly, c-Abl could be degraded with a dasatinib–VHL 
PROTAC at 1 µM, however, higher concentrations left c-Abl 
protein levels unaffected [86]. This is likely due to the so-
called ‘hook-effect’, where high concentrations of the PRO-
TACs block ternary complex formation, with either compo-
nent bound to individual PROTAC molecules. In contrast, 
both bosutinib- and dasatinib–pomalidomide PROTACs 
were able to efficiently degrade both BCR–Abl and c-Abl at 
around 100 nM concentrations and the dasatinib–pomalido-
mide PROTAC was efficient at reducing cell viability with a 
1000-fold higher efficiency over non-BCR–Abl driven cell 
lines [86].
PROTACs can also be utilized to degrade E3 ligases. 
To counteract the negative effects MDM2 has on cancer 
progression, the inhibitor MI-1242, which binds MDM2 
with low nanomolar affinities, was coupled to lenalido-
mide. Linker adjustments led to two very potent PROTACs, 
MD-222 and MD-224. These PROTACs are very efficient at 
degrading MDM2 and, in turn, stabilize p53 and inhibit cell 
proliferation at low nanomolar doses. Similar to BCR–Abl, 
this could not be achieved by the use of a VHL warhead [87].
VHL
One of the most studied E3 ligase adaptors for PROTAC 
development is the VHL tumour suppressor. As described 
in the AdPROM section, VHL acts as the substrate recep-
tor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α 
for its ubiquitination and degradation [88]. Under normoxic 
conditions, the VHL–HIF1α interaction is mediated through 
a hydroxyproline residue on HIF1α [49]. This hydroxypro-
line residue was the starting point for a peptidic ligand mol-
ecule with an  IC50 value of 4.1 µM for VHL binding at the 
HIF1α binding site [89], which could be improved to sub-
micromolar affinity [90]. Since peptidic molecules provide 
a challenge in terms of cell permeability of compounds, the 
peptidic VHL-binding portion was substituted subsequently 
by a small molecule, which retained the critical hydroxy-
proline [20]. Using a warhead targeting either the estrogen-
related receptor alpha (ERRα) [91] or the serine threonine 
kinase RIPK2, efficient degradation of both proteins could 
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be achieved with doses ranging from 3 nM (RIPK2) to 
100 nM (ERRα) [20]. Similar positive outcomes could be 
achieved with PROTACs targeting TANK-binding kinase 1 
(TBK1) [92], and ALK, where a clear correlation between 
efficacy in inhibiting cell proliferation and ALK driver status 
in different cell lines could be observed [93]. BRD4, which 
was efficiently degraded with a CRBN PROTAC [84], could 
also be targeted using a VHL-recruiting warhead. However, 
in this case, the BRD inhibitor JQ1 was chosen. While the 
PROTAC exhibited a clear preference for BRD4, BRD2 and 
3 were also degraded at either high concentrations or pro-
longed treatments [94].
More recently, homo-PROTACs for VHL have been 
developed. These molecules harbour two VHL binding 
moieties, rendering VHL both the recruiter as well as the 
ubiquitination substrate [95]. The most active compound, 
CM11, specifically depleted the long isoform of VHL, 
VHL30, within 4 h at 10 nM concentration, providing an 
intriguing tool for research on isoform specific functions 
of VHL.
c‑IAP PROTACs and specific and non‑genetic 
IAP‑dependent protein erasers (SNIPERs)
Cellular inhibitor of apoptosis 1 and 2 (c-IAP1 an c-IAP2) 
proteins were initially identified as inhibitors of caspase 3 
and 7, which bind caspases through their baculovirus IAP 
repeat (BIR) domains [96]. c-IAP proteins were later shown 
to regulate components of the NF-κB signalling pathway 
through their RING domain catalytic activity [97]. A dec-
ade ago, methyl-bestatin (ME-BS) was identified as a potent 
binder of c-IAP1, which induced autoubiquitination and 
degradation of c-IAP1 by binding its BIR3 domain [98]. In 
an initial PROTAC approach for c-IAP, ME-BS was cou-
pled to all-trans retinoic acid (ATRA), which binds cellular 
retinoic acid binding protein (CRABP-1 and -2), with the 
latter chosen due to the involvement of CRABP1/2 in Alz-
heimer’s disease, neuroblastoma, Wilms tumor, and head 
and neck squamous cell carcinoma [99]. PROTAC treat-
ment of cells expressing c-IAP1 and either CRABP-1 or 
CRABP-2 reduced levels of both c-IAP1 and either CRABP 
protein. Using the PROTAC on neuroblastoma, degradation 
of CRABP-2 resulted in reduced cell migration [99]. In an 
attempt to improve both the stability and affinity of the com-
pound, the ME-BS moiety was replaced with MV1, a potent 
binder of c-IAP1, c-IAP2 and XIAP [100]. Treatment of 
cells with this new PROTAC also induced efficient degrada-
tion of both c-IAP1 and CRABP-2 and blocked proliferation 
of neuroblastoma cells; however, the effects on either c-IAP2 
or XIAP were not analysed [100].
A subgroup of c-IAP PROTACs are commonly referred 
to as ‘specific and non-genetic IAP-dependent protein eras-
ers’ (SNIPERs) [101, 102]. To date, SNIPERs that target 
CRABP-2 [101], estrogen receptor alpha (ERα) [103], and 
transforming acidic coiled-coil-3 (TACC3) [104] have been 
generated, and in each case, successful degradation of the 
target protein has been demonstrated. To improve on the 
cIAP1 ligand-binding affinity, the IAP antagonist LCL161 
was chosen as an alternative cIAP1-binding moiety to create 
a novel SNIPER. Using this new approach, the authors dem-
onstrated robust degradation of ERα, the chronic myeloid 
leukemia (CML)-causative BCR–Abl fusion protein, BRD4 
and PDE4 proteins in cells [102].
Keap1‑based PROTACs
Recently, a peptide PROTAC was developed that was able 
to tether Kelch-like ECH-associated protein-1 (Keap1) and 
Tau into a ternary complex [105]. Keap1 functions as a 
substrate receptor unit for the cullin3–RBX1 complex, tar-
geting nuclear factor erythroid 2 related factor 2 (Nrf2) for 
ubiquitination under physiological conditions, while oxi-
dative stress inactivates Keap1, leading to accumulation of 
active Nrf2 [106]. A peptide inhibitor of the Nrf2–Keap1 
interaction had been developed previously, with an appar-
ent  KD of 2.8 nM for Keap1 binding [107]. To develop 
a peptide PROTAC to recruit the microtubule associated 
protein Tau to Keap1, this peptide was fused to a short 
peptide sequence of β-tubulin (YQQYQDATADEQG), 
which in turn was fused to a C-terminal poly-d-arginine 
sequence for enhanced cell permeability of the peptide 
[105]. Generation of the full-length peptide decreased 
Keap1 affinity tenfold and exhibited affinity towards Tau 
in the sub-micromolar range. This PROTAC, termed pep-
tide 1, was able to degrade overexpressed GFP-tagged Tau 
in different cell lines at 20 µM after 6–12 h of treatment 
times to various degrees.
HALO and dTAG PROTACs
As PROTACs require highly selective small molecule 
binders of POIs, currently they have limited utility against 
the vast majority of endogenous proteins. Developing 
selective high-affinity binders of POIs is both resource- 
and time-intensive process. Therefore, moieties that recog-
nize polypeptide tags, such as HALO and dTAG that could 
be inserted into POIs by CRISPR/Cas9 genome editing, 
offer opportunities for inducible degradation of POIs by 
using the tag-specific PROTACs (such as HaloPROTACs 
and dTAG-13, respectively) [108, 109]. HaloPROTACs, 
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which bind to the HALO tag on POIs on one side and VHL 
on the other, have been successfully employed to rapidly 
and inducibly degrade HALO-tagged POIs through the 
VHL/CUL2/RBX1-dependent UPS [109]. However, one 
of the limitations of using the HALO tag is its apparent 
large size (~ 33 kDa). This has the potential of affecting 
the function of the POI by obstructing key interactors, or 
substrates from accessing the POI, and in certain cases, 
the HALO tag itself might become the primary target of 
ubiquitination and degradation.
To overcome this, a smaller polypeptide tag that also 
harnesses a high-affinity PROTAC-binding moiety is 
desirable. Excitingly, Nabet et al. recently described such a 
system using an FKBP12(F36V) mutant (dTAG; ~ 12 kDa) 
[108]. The authors exploited an FKBP12-F36V-directed 
ligand called AP1867 (Ariad Pharmaceuticals) to gener-
ate a heterobifunctional PROTAC dTAG-13 that recruits 
dTAG to CRBN, and thereby degrades dTAG-fused POIs 
[108]. This approach proved successful in degrading 
dTAG–BRD4 fusion proteins generated by CRISPR/Cas9 
gene editing, and showed selective, rapid degradation of 
dTAG–BRD4 upon ligand treatment [108]. The authors 
extended this analysis and showcased consistent utility in 
degrading dTAG–KRAS–G12V and dTAG–EZH2 proteins 
overexpressed in mammalian cells. However, the authors 
noted varying rates of POI degradation, depending on 
the POI used, possibly owing to limited accessibility of 
the dTAG ligand in different subcellular compartments 
[108]. The efficacy of dTAG-13 to degrade overexpressed 
dTAG–KRAS–G12V was shown in mice, thereby estab-
lishing the dTAG system as an elegant FKBP12-based 
proteolytic system [108].
Future perspectives
The field of targeted proteolysis has taken huge strides in a 
relatively short period of time, both in terms of its develop-
ment as a robust research tool, and its potential in therapeu-
tic applications. While cell-permeable and selective small 
molecule POI degraders, such as PROTACs and SNIPERs, 
remain the ultimate choice in both research and therapeutics, 
the availability of other degron and nanobody-based targeted 
proteolytic tools offer more rapid opportunities to achieve 
targeted POI degradation. Developing small molecule 
PROTACs, SNIPERs and IMiDs to degrade specific POIs 
remains extremely challenging, as the generation of high-
affinity and selective POI-binding ligands that can be fused 
with the E3-binding ligands is costly and time-consuming. 
As a consequence, any rapid, targeted proteolytic approaches 
that can achieve the desired loss-of-function phenotypes 
have the potential to streamline POIs for the development 
of costly cell-permeable proteolytic small molecules, such as 
PROTACs. In this context, AiD and nanobody-based degra-
dation systems such as AdPROM offer much promise.
The premise for targeted proteolysis lies in harnessing 
the cellular ubiquitination machinery and the proteolytic 
pathways. Although there are over 600 E3 ubiquitin ligases 
encoded by the human genome, this review has demon-
strated that only a handful of E3 ubiquitin ligases have been 
utilized by the current targeted proteolytic methods. Increas-
ing the portfolio of E3 ubiquitin ligases that promote effi-
cient proteolysis is desirable to enhance the capabilities of 
targeted proteolytic technologies. In this context, nanobody-
based technologies such as AdPROM can rapidly inform 
whether a specific E3 ligase is a suitable candidate [19]. For 
any targeted proteolytic system to work effectively, the POI 
when recruited to the E3 ligase component has to present 
lysine (or other) residues for ubiquitination. In cases where 
the POI is recruited to the E3 ligase component, but is not 
degraded, absence of POI ubiquitination might render the 
proteolytic system ineffective. For some proteins, it might 
transpire that the UPS is not able to cause proteolysis of a 
POI despite its ubiquitination. All of the current targeted 
proteolytic systems utilize the UPS to achieve POI degra-
dation. However, harnessing ubiquitin-mediated lysosomal 
degradation of POIs could also offer an expansion to the 
targeted proteolytic toolkit.
Most of the targeted proteolytic systems that require 
tagging of the POI with a polypeptide tag, such as GFP or 
dTAG, using CRISPR/Cas9 are useful for understanding 
POI function, but are limited in scope to the cell systems 
in which CRISPR/Cas9 modifications are feasible. Moreo-
ver, tagging proteins can compromise the structural integ-
rity, subcellular distribution and biological activity of the 
POI itself. Ideally, any system that can target endogenous, 
unmodified POIs for degradation is desirable and enables 
research on the POI function in any cell line. Other than 
PROTACs, the AdPROM system offers an ideal toolkit to 
rapidly degrade endogenous POIs, provided there are selec-
tive POI-targeting polypeptides. These POI-targeting poly-
peptides can either be single chain antibodies (e.g. variable 
domains from camelid or shark-derived heavy chain only 
antibodies, nanobodies), or a variety of synthetic polypep-
tide scaffolds that bind POIs such as fibronectin type III 
domain-based monobodies [110, 111], designed ankyrin 
repeats (DARPINs) [112, 113], cystatin-derived affimers 
[114] or Affibodies derived from the Z-domain of staphylo-
coccal protein A [115]. These small polypeptide scaffolds 
consist of a stable backbone and variable loop regions, 
which determine POI-binding specificity. The mutagenized 
variants are screened for their interaction with specific POIs, 
typically through phage display technologies [116].
Recent and ongoing advances have steadily increased the 
repertoire of small polypeptide high-affinity protein binders 
of different protein targets (Table 1) and more are likely 
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to follow. While high-affinity binders are already used for 
immunoprecipitation and immunofluorescence applications 
[117], their use with AdPROM and AdPROM-like technolo-
gies will vastly expand the toolkit for researchers. For any 
polypeptide POI-binder to be an effective degrader when 
incorporated into the AdPROM system, it has to bind the 
POI in cellulo. As such, AdPROM currently only works 
on intracellular targets. The templates for developing these 
high-affinity binders are bacterially expressed recombinant 
proteins, which allow for detection of unmodified targets. 
With more technological advances, designing small poly-
peptide binders that recognize particular conformations of 
the POI (e.g. active or phosphorylated protein states) may 
allow for targeted destruction of distinct subsets of the POI, 
to enable highly specific loss-of-function assays to be per-
formed, without interference from the non-relevant POI 
pools.
For many proteins known to be involved in driving dis-
eases, such as KRAS in many cancers, conventional drug 
development strategies often aimed at developing inhibitors 
have failed [118, 119]. In drug research, such proteins are 
labelled as “undruggable” targets. Targeted protein deg-
radation offers a fresh and potentially viable approach at 
drugging these targets. Indeed, some PROTACs, such as 
the androgen receptor degrader PROTAC, ARV-110, has 
shown pre-clinical efficacy against prostate cancer [120] 
and is now a candidate for clinical trials [121]. Even in 
the absence of robust PROTAC molecules to target a wide 
range of so-called undruggable POIs, nanobody-based tar-
geted proteolytic systems, such as AdPROM, can rapidly 
address the druggability of any given target in different dis-
ease models. Given the availability of multiple toolkits for 
targeted proteolysis, their utility in drug discovery research 
is undoubtable, and the coming years are sure to witness 
major advances.
Acknowledgements SR is supported by GlaxoSmithKline through 
the Division of Signal Transduction Therapy collaboration. LJF is 
supported by the UK MRC PhD studentship and the Queens Col-
lege Scholarship, University of Dundee. GPS is supported by the UK 
MRC (Grant MC_UU_12016/3) and the pharmaceutical companies 
supporting the Division of Signal Transduction Therapy (Boehringer-
Ingelheim, GlaxoSmithKline, Merck-Serono). The authors declare no 
conflicts of interests. The authors would like to apologize for any rel-
evant study that may have been missed inadvertently in this review.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Horvath P, Barrangou R (2010) CRISPR/Cas, the immune sys-
tem of bacteria and archaea. Science 327:167–170. https ://doi.
org/10.1126/scien ce.11795 55
 2. Jinek M, Chylinski K, Fonfara I et al (2012) A programmable 
dual-RNA-guided DNA endonuclease in adaptive bacterial 
immunity. Science 337:816–821. https ://doi.org/10.1126/scien 
ce.12258 29
 3. Sharpe JJ, Cooper TA (2017) Unexpected consequences: exon 
skipping caused by CRISPR-generated mutations. Genome Biol 
18:109. https ://doi.org/10.1186/s1305 9-017-1240-0
 4. El-Brolosy MA, Stainier DYR (2017) Genetic compensation: a 
phenomenon in search of mechanisms. PLoS Genet 13:e1006780. 
https ://doi.org/10.1371/journ al.pgen.10067 80
 5. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, pros-
pects and challenges. Adv Drug Deliv Rev 59:75–86. https ://doi.
org/10.1016/J.ADDR.2007.03.005
 6. Kawasaki H, Taira K, Morris KV (2005) siRNA induced tran-
scriptional gene silencing in mammalian cells. Cell Cycle 4:442–
448. https ://doi.org/10.4161/cc.4.3.1520
 7. Tachibana-Konwalski K, Godwin J, Van Der Weyden L et al 
(2010) Rec8-containing cohesin maintains bivalents without 
turnover during the growing phase of mouse oocytes. Genes Dev 
24:2505–2516. https ://doi.org/10.1101/gad.60591 0
Table 1  Compilation of currently available high-affinity polypeptide binders of intracellular proteins
The list presents a compilation of some of the reported nanobodies, monobodies, DARPins and Affimers which might be suitable for use as POI-
targeting elements for AdPROM and AdPROM-like technologies. Note that only nanobodies for intracellular proteins/epitopes are listed in this 
table and appropriate references are cited
POI binder Targets
Nanobody GPCR Gβ1γ1 [122], C-Myc [123]; LMO2 [124]; endothelial and epithelial kinase (Etk) 
[125]; protein kinase Cε [126]; CapG [127]; RAS [128]; caspase-3 [129]; Bax [130]; 
hnRNP-K [131]; L-plastin [132–134]; fascin [135]; cortactin [135]; gelsolin [136]; 
huntington [137, 138]; α-synuclein [139]; β-catenin [140–142]; nuclear poly(A)-binding 
protein 1 (PABPN1) [143]; GFP [144], ASC [48]
Monobody β-Catenin [145]; Abl (SH2 domain) [111, 146]; SUMO1 [111, 147, 148]; Aurora A [149];
WDR5 [150]; H/K-RAS [151]; GFP [111]; Erk-2 [152]; ubiquitin [110]
DARPIN GFP [153]; tubulin [154]; caspase-2 [155, 156]; caspase-7 [155, 156]; H/K/N-RAS [157]
Affimer/Affibody p85α [158]; GRB2 [158]; GRB7 [158]; GRB10 [158]; GRB14 [158]; F-actin [159]; 
SUMO1 [160]; SUMO2 [160]; SUMO1/2 [160]; c-JUN [161]; amyloid-beta [162, 163]
Advances in targeted degradation of endogenous proteins 
1 3
 8. Jackson AL, Bartz SR, Schelter J et al (2003) Expression profil-
ing reveals off-target gene regulation by RNAi. Nat Biotechnol 
21:635–637. https ://doi.org/10.1038/nbt83 1
 9. Mockenhaupt S, Grosse S, Rupp D et al (2015) Alleviation of 
off-target effects from vector-encoded shRNAs via codelivered 
RNA decoys. Proc Natl Acad Sci 112:E4007–E4016. https ://doi.
org/10.1073/PNAS.15104 76112 
 10. Pickart CM, Eddins MJ (2004) Ubiquitin: structures, functions, 
mechanisms. Biochim Biophys Acta 1695:55–72. https ://doi.
org/10.1016/j.bbamc r.2004.09.019
 11. Roos-Mattjus P, Sistonen L (2004) The ubiquitin-proteasome 
pathway. Ann Med 36:285–295
 12. Komander D, Rape M (2012) The ubiquitin code. Annu Rev 
Biochem 81:203–229. https ://doi.org/10.1146/annur ev-bioch 
em-06031 0-17032 8
 13. Yau R, Rape M (2016) The increasing complexity of the ubiq-
uitin code. Nat Cell Biol 18:579–586. https ://doi.org/10.1038/
ncb33 58
 14. Akutsu M, Dikic I, Bremm A (2016) Ubiquitin chain diversity 
at a glance. J Cell Sci 129:875–880. https ://doi.org/10.1242/
jcs.18395 4
 15. Adams J (2003) The proteasome: structure, function, and role in 
the cell. Cancer Treat Rev 29(Suppl 1):3–9
 16. Budenholzer L, Cheng CL, Li Y, Hochstrasser M (2017) Protea-
some structure and assembly. J Mol Biol 429:3500–3524. https 
://doi.org/10.1016/j.jmb.2017.05.027
 17. Finley D (2009) Recognition and processing of ubiquitin-pro-
tein conjugates by the proteasome. Ann Rev Biochem 78:477–
513. https ://doi.org/10.1146/annur ev.bioch em.78.08150 
7.10160 7
 18. Fulcher LJ, Macartney T, Bozatzi P et al (2016) An affinity-
directed protein missile system for targeted proteolysis. Open 
Biol 6:160255. https ://doi.org/10.1098/rsob.16025 5
 19. Fulcher LJ, Hutchinson LD, Macartney TJ et al (2017) Target-
ing endogenous proteins for degradation through the affinity-
directed protein missile system. Open Biol 7:170066. https ://doi.
org/10.1098/rsob.17006 6
 20. Bondeson DP, Mares A, Smith IED et al (2015) Catalytic in vivo 
protein knockdown by small-molecule PROTACs. Nat Chem 
Biol 11:611–617. https ://doi.org/10.1038/nchem bio.1858
 21. Natsume T, Kiyomitsu T, Saga Y, Kanemaki MT (2016) Rapid 
protein depletion in human cells by auxin-inducible degron tag-
ging with short homology donors. Cell Rep 15:210–218. https ://
doi.org/10.1016/J.CELRE P.2016.03.001
 22. Navarro R, Chen LC, Rakhit R, Wandless TJ (2016) A novel 
destabilizing domain based on a small-molecule dependent fluo-
rophore. ACS Chem Biol 11:2101–2104. https ://doi.org/10.1021/
acsch embio .6b002 34
 23. Banaszynski LA, Chen L, Maynard-Smith LA et al (2006) A 
rapid, reversible, and tunable method to regulate protein function 
in living cells using synthetic small molecules. Cell 126:995–
1004. https ://doi.org/10.1016/j.cell.2006.07.025
 24. Nishimura K, Fukagawa T, Takisawa H et al (2009) An auxin-
based degron system for the rapid depletion of proteins in non-
plant cells. Nat Methods 6:917–922. https ://doi.org/10.1038/
nmeth .1401
 25. Tan X, Irina Calderon-Villalobos LA, Sharon M et al (2007) 
Mechanism of auxin perception by the TIR1 ubiquitin ligase. 
Nature 446:640–645. https ://doi.org/10.1038/natur e0573 1
 26. Folkes LK, Dennis MF, Stratford MR et al (1999) Peroxidase-
catalyzed effects of indole-3-acetic acid and analogues on 
lipid membranes, DNA, and mammalian cells in vitro. Bio-
chem Pharmacol 57:375–382. https ://doi.org/10.1016/S0006 
-2952(98)00323 -2
 27. Yamada R, Murai K, Uchida N et al (2018) A super strong engi-
neered auxin–TIR1 pair. Plant Cell Physiol 59:1538–1544. https 
://doi.org/10.1093/pcp/pcy12 7
 28. Dohmen R, Wu P, Varshavsky A (1994) Heat-inducible degron: a 
method for constructing temperature-sensitive mutants. Science 
263:1273–1276. https ://doi.org/10.1126/scien ce.81221 09
 29. Daniel K, Icha J, Horenburg C et al (2018) Conditional control of 
fluorescent protein degradation by an auxin-dependent nanobody. 
Nat Commun 9:3297. https ://doi.org/10.1038/s4146 7-018-05855 
-5
 30. Sehgal SN, Baker H, Vézina C (1975) Rapamycin (AY-22,989), 
a new antifungal antibiotic. II. Fermentation, isolation and 
characterization. J Antibiot (Tokyo) 28:727–732. https ://doi.
org/10.7164/antib iotic s.28.727
 31. Liberles SD, Diver ST, Austin DJ, Schreiber SL (1997) Inducible 
gene expression and protein translocation using nontoxic ligands 
identified by a mammalian three-hybrid screen. Proc Natl Acad 
Sci 94:7825–7830. https ://doi.org/10.1073/PNAS.94.15.7825
 32. Stankunas K, Bayle JH, Gestwicki JE et al (2003) Conditional 
protein alleles using knockin mice and a chemical inducer of 
dimerization. Mol Cell 12:1615–1624. https ://doi.org/10.1016/
S1097 -2765(03)00491 -X
 33. Kumagai A, Ando R, Miyatake H et al (2013) A bilirubin-induc-
ible fluorescent protein from eel muscle. Cell 153:1602–1611. 
https ://doi.org/10.1016/j.cell.2013.05.038
 34. Chung HK, Jacobs CL, Huo Y et al (2015) Tunable and reversible 
drug control of protein production via a self-excising degron. Nat 
Chem Biol 11:713–720. https ://doi.org/10.1038/nchem bio.1869
 35. Failla C, Tomei L, De Francesco R (1994) Both NS3 and NS4A 
are required for proteolytic processing of hepatitis C virus non-
structural proteins. J Virol 68:3753–3760
 36. Lin MZ, Glenn JS, Tsien RY (2008) A drug-controllable tag 
for visualizing newly synthesized proteins in cells and whole 
animals. Proc Natl Acad Sci 105:7744–7749. https ://doi.
org/10.1073/pnas.08030 60105 
 37. Nisole S, Stoye JP, Saïb A (2005) TRIM family proteins: retro-
viral restriction and antiviral defence. Nat Rev Microbiol 3:799–
808. https ://doi.org/10.1038/nrmic ro124 8
 38. James LC, Keeble AH, Khan Z et al (2007) Structural basis for 
PRYSPRY-mediated tripartite motif (TRIM) protein function. 
Proc Natl Acad Sci 104:6200–6205. https ://doi.org/10.1073/
pnas.06091 74104 
 39. Mallery DL, McEwan WA, Bidgood SR et al (2010) Antibodies 
mediate intracellular immunity through tripartite motif-contain-
ing 21 (TRIM21). Proc Natl Acad Sci 107:19985–19990. https 
://doi.org/10.1073/pnas.10140 74107 
 40. Clift D, McEwan WA, Labzin LI et al (2017) A method for 
the acute and rapid degradation of endogenous proteins. 
Cell 171:1692.e18–1706.e18. https ://doi.org/10.1016/j.
cell.2017.10.033
 41. Kamura T, Maenaka K, Kotoshiba S et al (2004) VHL-box and 
SOCS-box domains determine binding specificity for Cul2-
Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 
18:3055–3065. https ://doi.org/10.1101/gad.12524 04
 42. Sha F, Gencer EB, Georgeon S et al (2013) Dissection of the 
BCR–ABL signaling network using highly specific monobody 
inhibitors to the SHP2 SH2 domains. Proc Natl Acad Sci USA 
110:14924–14929. https ://doi.org/10.1073/pnas.13036 40110 
 43. Bosu DR, Kipreos ET (2008) Cullin-RING ubiquitin ligases: 
global regulation and activation cycles. Cell Div 3:7. https ://doi.
org/10.1186/1747-1028-3-7
 44. Cardote TAF, Gadd MS, Ciulli A (2017) Crystal structure of 
the Cul2–Rbx1–EloBC–VHL ubiquitin ligase complex. Struc-
ture 25:901.e3–911.e3. https ://doi.org/10.1016/j.str.2017.04.009
 45. Zhao Y, Sun Y (2013) Cullin-RING ligases as attractive anti-
cancer targets. Curr Pharm Des 19:3215–3225
 S. Röth et al.
1 3
 46. Enchev RI, Schulman BA, Peter M (2015) Protein neddylation: 
beyond cullin-RING ligases. Nat Rev Mol Cell Biol 16:30–44. 
https ://doi.org/10.1038/nrm39 19
 47. Soucy TA, Smith PG, Milhollen MA et al (2009) An inhibitor 
of NEDD8-activating enzyme as a new approach to treat cancer. 
Nature 458:732–736. https ://doi.org/10.1038/natur e0788 4
 48. Schmidt FI, Lu A, Chen JW et al (2016) A single domain anti-
body fragment that recognizes the adaptor ASC defines the 
role of ASC domains in inflammasome assembly. J Exp Med 
213:771–790. https ://doi.org/10.1084/jem.20151 790
 49. Yu F, White SB, Zhao Q, Lee FS (2001) HIF-1alpha binding to 
VHL is regulated by stimulus-sensitive proline hydroxylation. 
Proc Natl Acad Sci USA 98:9630–9635. https ://doi.org/10.1073/
pnas.18134 1498
 50. Wang S, Tang NH, Lara-Gonzalez P et al (2017) A toolkit for 
GFP-mediated tissue-specific protein degradation in C. elegans. 
Development 144:2694–2701. https ://doi.org/10.1242/dev.15009 
4
 51. Caussinus E, Kanca O, Affolter M (2012) Fluorescent fusion 
protein knockout mediated by anti-GFP nanobody. Nat Struct 
Mol Biol 19:117–121. https ://doi.org/10.1038/nsmb.2180
 52. Armenti ST, Lohmer LL, Sherwood DR, Nance J (2014) Repur-
posing an endogenous degradation system for rapid and targeted 
depletion of C. elegans proteins. Development 141:4640–4647. 
https ://doi.org/10.1242/dev.11504 8
 53. DeRenzo C, Reese KJ, Seydoux G (2003) Exclusion of germ 
plasm proteins from somatic lineages by cullin-dependent degra-
dation. Nature 424:685–689. https ://doi.org/10.1038/natur e0188 
7
 54. Caussinus E, Kanca O, Affolter M (2013) Protein knockouts in 
living eukaryotes using deGradFP and green fluorescent protein 
fusion targets. In: Current protocols in protein science. Wiley, 
Hoboken, pp 30.2.1–30.2.13
 55. Balchin D, Hayer-Hartl M, Hartl FU (2016) In vivo aspects of 
protein folding and quality control. Science 353:aac4354. https 
://doi.org/10.1126/scien ce.aac43 54
 56. Neklesa TK, Tae HS, Schneekloth AR et al (2011) Small-mole-
cule hydrophobic tagging-induced degradation of HaloTag fusion 
proteins. Nat Chem Biol 7:538–543. https ://doi.org/10.1038/
nchem bio.597
 57. Gustafson JL, Neklesa TK, Cox CS et al (2015) Small-molecule-
mediated degradation of the androgen receptor through hydro-
phobic tagging. Angew Chem Int Ed 54:9659–9662. https ://doi.
org/10.1002/anie.20150 3720
 58. Murata S, Chiba T, Tanaka K (2003) CHIP: a quality-control 
E3 ligase collaborating with molecular chaperones. Int J Bio-
chem Cell Biol 35:572–578. https ://doi.org/10.1016/S1357 
-2725(02)00394 -1
 59. Murata S, Minami Y, Minami M et al (2001) CHIP is a chap-
erone-dependent E3 ligase that ubiquitylates unfolded protein. 
EMBO Rep 2:1133–1138. https ://doi.org/10.1093/embo-repor 
ts/kve24 6
 60. Gao N, Chu T, Li Q et al (2017) Hydrophobic tagging-medi-
ated degradation of Alzheimer’ s disease related Tau. RSC Adv 
7:40362–40366. https ://doi.org/10.1039/C7RA0 5347A 
 61. Xie T, Lim SM, Westover KD et al (2014) Pharmacological tar-
geting of the pseudokinase Her3. Nat Chem Biol 10:1006–1012. 
https ://doi.org/10.1038/nchem bio.1658
 62. Sakamoto KM, Kim KB, Kumagai A et al (2001) Protacs: chi-
meric molecules that target proteins to the Skp1-Cullin-F box 
complex for ubiquitination and degradation. Proc Natl Acad Sci 
98:8554–8559. https ://doi.org/10.1073/pnas.14123 0798
 63. Niazi S, Purohit M, Niazi JH (2018) Role of p53 circuitry in 
tumorigenesis: a brief review. Eur J Med Chem 158:7–24. https 
://doi.org/10.1016/J.EJMEC H.2018.08.099
 64. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes 
the rapid degradation of p53. Nature 387:296–299. https ://doi.
org/10.1038/38729 6a0
 65. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a 
ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25–
27. https ://doi.org/10.1016/S0014 -5793(97)01480 -4
 66. Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of 
the p53 pathway by small-molecule antagonists of MDM2. Sci-
ence 303:844–848. https ://doi.org/10.1126/scien ce.10924 72
 67. Schneekloth AR, Pucheault M, Tae HS, Crews CM (2008) Tar-
geted intracellular protein degradation induced by a small mol-
ecule: en route to chemical proteomics. Bioorg Med Chem Lett 
18:5904–5908. https ://doi.org/10.1016/J.BMCL.2008.07.114
 68. Hines J, Lartigue S, Dong H et al (2018) MDM2-recruiting 
PROTAC offers superior, synergistic anti-proliferative activity 
via simultaneous degradation of BRD4 and stabilization of p53. 
Cancer Res. https ://doi.org/10.1158/0008-5472.can-18-2918
 69. Fischer ES, Böhm K, Lydeard JR et al (2014) Structure of the 
DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. 
Nature 512:49–53. https ://doi.org/10.1038/natur e1352 7
 70. Petzold G, Fischer ES, Thomä NH (2016) Structural basis of 
lenalidomide-induced CK1α degradation by the CRL4CRBN 
ubiquitin ligase. Nature 532:127–130. https ://doi.org/10.1038/
natur e1697 9
 71. Krönke J, Fink EC, Hollenbach PW et al (2015) Lenalidomide 
induces ubiquitination and degradation of CK1α in del(5q) MDS. 
Nature 523:183–188. https ://doi.org/10.1038/natur e1461 0
 72. Kronke J, Udeshi ND, Narla A et  al (2014) Lenalidomide 
causes selective degradation of IKZF1 and IKZF3 in multiple 
myeloma cells. Science 343:301–305. https ://doi.org/10.1126/
scien ce.12448 51
 73. Cecconi F, Proetzel G, Alvarez-Bolado G et al (1997) Expres-
sion of Meis2, a Knotted-related murine homeobox gene, 
indicates a role in the differentiation of the forebrain and 
the somitic mesoderm. Dev Dyn 210:184–190. https ://doi.
org/10.1002/(SICI)1097-0177(19971 0)210:2<184::AID-
AJA10 >3.0.CO;2-E
 74. Ito T, Ando H, Suzuki T et al (2010) Identification of a primary 
target of thalidomide teratogenicity. Science 327:1345–1350. 
https ://doi.org/10.1126/scien ce.11773 19
 75. Millrine D, Kishimoto T (2017) a brighter side to thalidomide: 
its potential use in immunological disorders. Trends Mol Med 
23:348–361. https ://doi.org/10.1016/j.molme d.2017.02.006
 76. Sheskin J (1965) Thalidomide in the treatment of lepra reac-
tions. Clin Pharmacol Ther 6:303–306. https ://doi.org/10.1002/
cpt19 65633 03
 77. Matyskiela ME, Lu G, Ito T et al (2016) A novel cereblon 
modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. 
Nature 535:252–257. https ://doi.org/10.1038/natur e1861 1
 78. Sievers QL, Petzold G, Bunker RD et al (2018) Defining the 
human C2H2 zinc finger degrome targeted by thalidomide 
analogs through CRBN. Science 362:eaat0572. https ://doi.
org/10.1126/scien ce.aat05 72
 79. Powell CE, Gao Y, Tan L et al (2018) Chemically induced deg-
radation of anaplastic lymphoma kinase (ALK). J Med Chem 
61:4249–4255. https ://doi.org/10.1021/acs.jmedc hem.7b016 55
 80. Zhang C, Han X-R, Yang X et al (2018) Proteolysis targeting 
chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). 
Eur J Med Chem 151:304–314. https ://doi.org/10.1016/J.
EJMEC H.2018.03.071
 81. Yang Z, Yik JHN, Chen R et al (2005) Recruitment of P-TEFb 
for stimulation of transcriptional elongation by the bromo-
domain protein Brd4. Mol Cell 19:535–545. https ://doi.
org/10.1016/J.MOLCE L.2005.06.029
Advances in targeted degradation of endogenous proteins 
1 3
 82. Lovén J, Hoke HA, Lin CY et al (2013) Selective inhibition 
of tumor oncogenes by disruption of super-enhancers. Cell 
153:320–334. https ://doi.org/10.1016/j.cell.2013.03.036
 83. Coudé M-M, Braun T, Berrou J et al (2015) BET inhibitor 
OTX015 targets BRD2 and BRD4 and decreases c-MYC in 
acute leukemia cells. Oncotarget 6:17698–17712. https ://doi.
org/10.18632 /oncot arget .4131
 84. Lu J, Qian Y, Altieri M et al (2015) Hijacking the E3 ubiq-
uitin ligase cereblon to efficiently target BRD4. Chem Biol 
22:755–763. https ://doi.org/10.1016/j.chemb iol.2015.05.009
 85. Winter GE, Buckley DL, Paulk J et al (2015) Phthalimide con-
jugation as a strategy for in vivo target protein degradation. 
Science 348:1376–1381. https ://doi.org/10.1126/scien ce.aab14 
33
 86. Lai AC, Toure M, Hellerschmied D et  al (2016) Modular 
PROTAC design for the degradation of oncogenic BCR-ABL. 
Angew Chem Int Ed 55:807–810. https ://doi.org/10.1002/
anie.20150 7634
 87. Li Y, Yang J, Aguilar A et al (2019) Discovery of MD-224 
as a first-in-class, highly potent, and efficacious proteolysis 
targeting chimera murine double minute 2 degrader capable of 
achieving complete and durable tumor regression. J Med Chem 
62(2):448–466. https ://doi.org/10.1021/acs.jmedc hem.8b009 09
 88. Ohh M, Park C, Ivan M et al (2000) Ubiquitination of HIF 
requires direct binding to the beta-domain of the vHL protein. 
Nat Cell Biol 2:423–427
 89. Buckley DL, Van Molle I, Gareiss PC et al (2012) Targeting the 
von Hippel-Lindau E3 ubiquitin ligase using small molecules to 
disrupt the vHL/HIF-1α interaction. J Am Chem Soc 134:4465–
4468. https ://doi.org/10.1021/ja209 924v
 90. Buckley DL, Gustafson JL, Van Molle I et al (2012) Small-mol-
ecule inhibitors of the interaction between the E3 Ligase VHL 
and HIF1α. Angew Chem Int Ed 51:11463–11467. https ://doi.
org/10.1002/anie.20120 6231
 91. Patch RJ, Searle LL, Kim AJ et al (2011) Identification of dia-
ryl ether-based ligands for estrogen-related receptor α as poten-
tial antidiabetic agents. J Med Chem 54:788–808. https ://doi.
org/10.1021/jm101 063h
 92. Crew AP, Raina K, Dong H et al (2018) Identification and charac-
terization of von Hippel-Lindau-recruiting proteolysis targeting 
chimeras (PROTACs) of TANK-binding kinase 1. J Med Chem 
61:583–598. https ://doi.org/10.1021/acs.jmedc hem.7b006 35
 93. Kang CH, Lee DH, Lee CO et al (2018) Induced protein deg-
radation of anaplastic lymphoma kinase (ALK) by proteolysis 
targeting chimera (PROTAC). Biochem Biophys Res Commun 
505:542–547. https ://doi.org/10.1016/J.BBRC.2018.09.169
 94. Zengerle M, Chan KH, Ciulli A (2015) Selective small molecule 
induced degradation of the BET bromodomain protein BRD4. 
ACS Chem Biol 10:1770–1777. https ://doi.org/10.1021/acsch 
embio .5b002 16
 95. Maniaci C, Hughes SJ, Testa A et al (2017) Homo-PROTACs: 
Bivalent small-molecule dimerizers of the VHL E3 ubiquitin 
ligase to induce self-degradation. Nat Commun 8:830. https ://
doi.org/10.1038/s4146 7-017-00954 -1
 96. Roy N, Deveraux QL, Takahashi R et al (1997) The c-IAP-1 and 
c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO 
J 16:6914–6925. https ://doi.org/10.1093/emboj /16.23.6914
 97. Kocab AJ, Duckett CS (2016) Inhibitor of apoptosis proteins as 
intracellular signaling intermediates. FEBS J 283:221–231. https 
://doi.org/10.1111/febs.13554 
 98. Sekine K, Takubo K, Kikuchi R et al (2008) Small molecules 
destabilize cIAP1 by activating auto-ubiquitylation. J Biol Chem 
283:8961–8968. https ://doi.org/10.1074/jbc.M7095 25200 
 99. Itoh Y, Ishikawa M, Naito M, Hashimoto Y (2010) Protein 
knockdown using methyl bestatin–ligand hybrid molecules: 
design and synthesis of inducers of ubiquitination-mediated 
degradation of cellular retinoic acid-binding proteins. J Am 
Chem Soc 132:5820–5826. https ://doi.org/10.1021/ja100 691p
 100. Itoh Y, Ishikawa M, Kitaguchi R et al (2012) Double protein 
knockdown of cIAP1 and CRABP-II using a hybrid molecule 
consisting of ATRA and IAPs antagonist. Bioorg Med Chem Lett 
22:4453–4457. https ://doi.org/10.1016/J.BMCL.2012.04.134
 101. Okuhira K, Ohoka N, Sai K et al (2011) Specific degradation of 
CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid 
molecules that crosslink cIAP1 and the target protein. FEBS Lett 
585:1147–1152. https ://doi.org/10.1016/j.febsl et.2011.03.019
 102. Ohoka N, Okuhira K, Ito M et al (2017) In vivo knockdown of 
pathogenic proteins via specific and nongenetic inhibitor of apop-
tosis protein (IAP)-dependent protein erasers (SNIPERs). J Biol 
Chem 292:4556–4570. https ://doi.org/10.1074/jbc.M116.76885 
3
 103. Ohoka N, Morita Y, Nagai K et al (2018) Derivatization of inhib-
itor of apoptosis protein (IAP) ligands yields improved inducers 
of estrogen receptor α degradation. J Biol Chem 293:6776–6790. 
https ://doi.org/10.1074/jbc.RA117 .00109 1
 104. Ohoka N, Nagai K, Hattori T et al (2014) Cancer cell death 
induced by novel small molecules degrading the TACC3 protein 
via the ubiquitin–proteasome pathway. Cell Death Dis 5:e1513. 
https ://doi.org/10.1038/cddis .2014.471
 105. Lu M, Liu T, Jiao Q et al (2018) Discovery of a Keap1-dependent 
peptide PROTAC to knockdown Tau by ubiquitination-proteas-
ome degradation pathway. Eur J Med Chem 146:251–259. https 
://doi.org/10.1016/j.ejmec h.2018.01.063
 106. Lu M-C, Ji J-A, Jiang Z-Y, You Q-D (2016) The Keap1-Nrf2-
ARE pathway as a potential preventive and therapeutic target: 
an update. Med Res Rev 36:924–963. https ://doi.org/10.1002/
med.21396 
 107. Lu M-C, Chen Z-Y, Wang Y-L et al (2015) Binding thermo-
dynamics and kinetics guided optimization of potent Keap1–
Nrf2 peptide inhibitors. RSC Adv 5:85983–85987. https ://doi.
org/10.1039/C5RA1 6262A 
 108. Nabet B, Roberts JM, Buckley DL et al (2018) The dTAG system 
for immediate and target-specific protein degradation. Nat Chem 
Biol 14:431–441. https ://doi.org/10.1038/s4158 9-018-0021-8
 109. Buckley DL, Raina K, Darricarrere N et al (2015) HaloPRO-
TACS: use of Small Molecule PROTACs to Induce Degradation 
of HaloTag Fusion Proteins. ACS Chem Biol 10:1831–1837. 
https ://doi.org/10.1021/acsch embio .5b004 42
 110. Koide A, Bailey CW, Huang X, Koide S (1998) The fibronectin 
type III domain as a scaffold for novel binding proteins. J Mol 
Biol 284:1141–1151. https ://doi.org/10.1006/JMBI.1998.2238
 111. Koide A, Wojcik J, Gilbreth RN et al (2012) Teaching an old 
scaffold new tricks: monobodies constructed using alternative 
surfaces of the FN3 scaffold. J Mol Biol 415:393–405. https ://
doi.org/10.1016/J.JMB.2011.12.019
 112. Binz HK, Stumpp MT, Forrer P et al (2003) Designing repeat 
proteins: well-expressed, soluble and stable proteins from combi-
natorial libraries of consensus ankyrin repeat proteins. J Mol Biol 
332:489–503. https ://doi.org/10.1016/S0022 -2836(03)00896 -9
 113. Binz HK, Amstutz P, Kohl A et al (2004) High-affinity bind-
ers selected from designed ankyrin repeat protein libraries. Nat 
Biotechnol 22:575–582. https ://doi.org/10.1038/nbt96 2
 114. Tiede C, Tang AAS, Deacon SE et al (2014) Adhiron: a stable 
and versatile peptide display scaffold for molecular recogni-
tion applications. Protein Eng Des Sel 27:145–155. https ://doi.
org/10.1093/prote in/gzu00 7
 115. Löfblom J, Feldwisch J, Tolmachev V et al (2010) Affibody 
molecules: engineered proteins for therapeutic, diagnostic and 
biotechnological applications. FEBS Lett 584:2670–2680. https 
://doi.org/10.1016/J.FEBSL ET.2010.04.014
 S. Röth et al.
1 3
 116. Banta S, Dooley K, Shur O (2013) Replacing antibodies: engi-
neering new binding proteins. Annu Rev Biomed Eng 15:93–113. 
https ://doi.org/10.1146/annur ev-bioen g-07181 2-15241 2
 117. Rothbauer U, Zolghadr K, Tillib S et al (2006) Targeting and 
tracing antigens in live cells with fluorescent nanobodies. Nat 
Methods 3:887–889. https ://doi.org/10.1038/nmeth 953
 118. Holderfield M (2018) Efforts to develop KRAS inhibitors. Cold 
Spring Harb Perspect Med 8:a031864. https ://doi.org/10.1101/
cshpe rspec t.a0318 64
 119. Cox AD, Fesik SW, Kimmelman AC et al (2014) Drugging the 
undruggable RAS: mission Possible? Nat Rev Drug Discov 
13:828–851. https ://doi.org/10.1038/nrd43 89
 120. Neklesa T, Snyder LB, Willard RR, et al (2018) Abstract 5236: 
ARV-110: an androgen receptor PROTAC degrader for prostate 
cancer. In: Cancer Research. American Association for Cancer 
Research, pp 5236–5236
 121. Mullard A (2019) First targeted protein degrader hits the clinic. 
In: Nat Rev Drug Discov. http://www.natur e.com/artic les/d4157 
3-019-00043 -6. Accessed 19 Mar 2019
 122. Gulati S, Jin H, Masuho I et al (2018) Targeting G protein-cou-
pled receptor signaling at the G protein level with a selective nan-
obody inhibitor. Nat Commun 9:1996. https ://doi.org/10.1038/
s4146 7-018-04432 -0
 123. Zeng J, Li HC, Tanaka T, Rabbitts TH (2015) Selection of human 
single domain antibodies recognizing the CMYC protein using 
enhanced intracellular antibody capture. J Immunol Methods 
426:140–143. https ://doi.org/10.1016/J.JIM.2015.08.009
 124. Tanaka T, Sewell H, Waters S et al (2011) Single domain intra-
cellular antibodies from diverse libraries: emphasizing dual 
functions of LMO2 protein interactions using a single VH 
domain. J Biol Chem 286:3707–3716. https ://doi.org/10.1074/
jbc.M110.18819 3
 125. Paz K, Brennan LA, Iacolina M et al (2005) Human single-
domain neutralizing intrabodies directed against Etk kinase: 
a novel approach to impair cellular transformation. Mol Can-
cer Ther 4:1801–1809. https ://doi.org/10.1158/1535-7163.
MCT-05-0174
 126. Summanen M, Granqvist N, Tuominen RK et al (2012) Kinetics 
of PKCε activating and inhibiting llama single chain antibodies 
and their effect on PKCε translocation in HeLa cells. PLoS One 
7:e35630. https ://doi.org/10.1371/journ al.pone.00356 30
 127. Van Impe K, Bethuyne J, Cool S et al (2013) A nanobody tar-
geting the F-actin capping protein CapG restrains breast cancer 
metastasis. Breast Cancer Res 15:R116. https ://doi.org/10.1186/
bcr35 85
 128. Tanaka T, Rabbitts TH (2003) Intrabodies based on intracellular 
capture frameworks that bind the RAS protein with high affinity 
and impair oncogenic transformation. EMBO J 22:1025–1035. 
https ://doi.org/10.1093/emboj /cdg10 6
 129. McGonigal K, Tanha J, Palazov E et al (2009) Isolation and func-
tional characterization of single domain antibody modulators of 
caspase-3 and apoptosis. Appl Biochem Biotechnol 157:226–
236. https ://doi.org/10.1007/s1201 0-008-8266-4
 130. Gueorguieva D, Li S, Walsh N et al (2006) Identification of 
single-domain, Bax-specific intrabodies that confer resistance 
to mammalian cells against oxidative-stress-induced apoptosis. 
FASEB J 20:2636–2638. https ://doi.org/10.1096/fj.06-6306fj e
 131. Inoue A, Sawata SY, Taira K, Wadhwa R (2007) Loss-of-function 
screening by randomized intracellular antibodies: identification 
of hnRNP-K as a potential target for metastasis. Proc Natl Acad 
Sci U S A 104:8983–8988. https ://doi.org/10.1073/pnas.06075 
95104 
 132. Delanote V, Vanloo B, Catillon M et al (2010) An alpaca sin-
gle-domain antibody blocks filopodia formation by obstructing 
L-plastin-mediated F-actin bundling. FASEB J 24:105–118. https 
://doi.org/10.1096/fj.09-13430 4
 133. De Clercq S, Zwaenepoel O, Martens E et al (2013) Nano-
body-induced perturbation of LFA-1/L-plastin phosphoryla-
tion impairs MTOC docking, immune synapse formation and 
T cell activation. Cell Mol Life Sci 70:909–922. https ://doi.
org/10.1007/s0001 8-012-1169-0
 134. De Clercq S, Boucherie C, Vandekerckhove J et al (2013) L-plas-
tin nanobodies perturb matrix degradation, podosome forma-
tion, stability and lifetime in THP-1 macrophages. PLoS One 
8:e78108. https ://doi.org/10.1371/journ al.pone.00781 08
 135. Van Audenhove I, Boucherie C, Pieters L et al (2014) Stratifying 
fascin and cortactin function in invadopodium formation using 
inhibitory nanobodies and targeted subcellular delocalization. 
FASEB J 28:1805–1818. https ://doi.org/10.1096/fj.13-24253 7
 136. Van den Abbeele A, De Clercq S, De Ganck A et al (2010) A 
llama-derived gelsolin single-domain antibody blocks gelsolin–
G-actin interaction. Cell Mol Life Sci 67:1519–1535. https ://doi.
org/10.1007/s0001 8-010-0266-1
 137. Colby DW, Chu Y, Cassady JP et al (2004) Potent inhibition of 
huntingtin aggregation and cytotoxicity by a disulfide bond-free 
single-domain intracellular antibody. Proc Natl Acad Sci USA 
101:17616–17621. https ://doi.org/10.1073/pnas.04081 34101 
 138. Colby DW, Garg P, Holden T et al (2004) Development of a 
human light chain variable domain (VL) intracellular antibody 
specific for the amino terminus of huntingtin via yeast surface 
display. J Mol Biol 342:901–912. https ://doi.org/10.1016/J.
JMB.2004.07.054
 139. Lynch SM, Zhou C, Messer A (2008) An scFv intrabody against 
the nonamyloid component of α-synuclein reduces intracellular 
aggregation and toxicity. J Mol Biol 377:136–147. https ://doi.
org/10.1016/J.JMB.2007.11.096
 140. Newnham LE, Wright MJ, Holdsworth G et al (2015) Func-
tional inhibition of β-catenin-mediated Wnt signaling by 
intracellular VHH antibodies. MAbs 7:180–191. https ://doi.
org/10.4161/19420 862.2015.98902 3
 141. Traenkle B, Emele F, Anton R et al (2015) Monitoring interac-
tions and dynamics of endogenous beta-catenin with intracellular 
nanobodies in living cells. Mol Cell Proteom 14:707–723. https 
://doi.org/10.1074/mcp.M114.04401 6
 142. Braun MB, Traenkle B, Koch PA et al (2016) Peptides in head-
lock—a novel high-affinity and versatile peptide-binding nano-
body for proteomics and microscopy. Sci Rep 6:19211. https ://
doi.org/10.1038/srep1 9211
 143. Verheesen P, de Kluijver A, van Koningsbruggen S et al (2006) 
Prevention of oculopharyngeal muscular dystrophy-associated 
aggregation of nuclear poly(A)-binding protein with a single-
domain intracellular antibody. Hum Mol Genet 15:105–111. 
https ://doi.org/10.1093/hmg/ddi43 2
 144. Fridy PC, Li Y, Keegan S et al (2014) A robust pipeline for 
rapid production of versatile nanobody repertoires. Nat Methods 
11:1253–1260. https ://doi.org/10.1038/nmeth .3170
 145. Yeh JT-H, Binari R, Gocha T et al (2013) PAPTi: a peptide 
aptamer interference toolkit for perturbation of protein–protein 
interaction networks. Sci Rep 3:1156. https ://doi.org/10.1038/
srep0 1156
 146. Wojcik J, Hantschel O, Grebien F et al (2010) A potent and highly 
specific FN3 monobody inhibitor of the Abl SH2 domain. Nat 
Struct Mol Biol 17:519–527. https ://doi.org/10.1038/nsmb.1793
 147. Berndt A, Wilkinson KA, Heimann MJ et al (2013) In vivo char-
acterization of the properties of SUMO1-specific monobodies. 
Biochem J 456:385–395. https ://doi.org/10.1042/BJ201 30241 
 148. Gilbreth RN, Truong K, Madu I et al (2011) Isoform-specific 
monobody inhibitors of small ubiquitin-related modifiers engi-
neered using structure-guided library design. Proc Natl Acad Sci 
108:7751–7756. https ://doi.org/10.1073/pnas.11022 94108 
Advances in targeted degradation of endogenous proteins 
1 3
 149. Pitsawong W, Buosi V, Otten R et al (2018) Dynamics of human 
protein kinase Aurora A linked to drug selectivity. Elife 7:231–
237. https ://doi.org/10.7554/eLife .36656 
 150. Gupta A, Xu J, Lee S et al (2018) Facile target validation in 
an animal model with intracellularly expressed monobodies. 
Nat Chem Biol 14:895–900. https ://doi.org/10.1038/s4158 
9-018-0099-z
 151. Spencer-Smith R, Koide A, Zhou Y et al (2017) Inhibition of 
RAS function through targeting an allosteric regulatory site. Nat 
Chem Biol 13:62–68. https ://doi.org/10.1038/nchem bio.2231
 152. Mann JK, Wood JF, Stephan AF et al (2013) Epitope-guided 
engineering of monobody binders for in vivo inhibition of Erk-2 
signaling. ACS Chem Biol 8:608–616. https ://doi.org/10.1021/
cb300 579e
 153. Hansen S, Stüber JC, Ernst P et al (2017) Design and applications 
of a clamp for green fluorescent protein with picomolar affinity. 
Sci Rep 7:1–16. https ://doi.org/10.1038/s4159 8-017-15711 -z
 154. Ahmad S, Pecqueur L, Dreier B et al (2016) Destabilizing an 
interacting motif strengthens the association of a designed 
ankyrin repeat protein with tubulin. Sci Rep 6:1–14. https ://doi.
org/10.1038/srep2 8922
 155. Schweizer A, Roschitzki-Voser H, Amstutz P et al (2007) Inhibi-
tion of Caspase-2 by a designed ankyrin repeat protein: specific-
ity, structure, and inhibition mechanism. Structure 15:625–636. 
https ://doi.org/10.1016/j.str.2007.03.014
 156. Seeger MA, Zbinden R, Flütsch A et al (2013) Design, construc-
tion, and characterization of a second-generation DARPin library 
with reduced hydrophobicity. Protein Sci 22:1239–1257. https ://
doi.org/10.1002/pro.2312
 157. Guillard S, Kolasinska-Zwierz P, Debreczeni J et  al (2017) 
Structural and functional characterization of a DARPin which 
inhibits Ras nucleotide exchange. Nat Commun 8:16111. https 
://doi.org/10.1038/ncomm s1611 1
 158. Tiede C, Bedford R, Heseltine SJ et al (2017) Affimer proteins 
are versatile and renewable affinity reagents. Elife 6:1–35. https 
://doi.org/10.7554/eLife .24903 
 159. Lopata A, Hughes R, Tiede C et al (2018) Affimer proteins for 
F-actin: novel affinity reagents that label F-actin in live and fixed 
cells. Sci Rep 8:6572. https ://doi.org/10.1038/s4159 8-018-24953 
-4
 160. Hughes DJ, Tiede C, Penswick N et al (2017) Generation of 
specific inhibitors of SUMO-1- and SUMO-2/3-mediated pro-
tein-protein interactions using Affimer (Adhiron) technology. Sci 
Signal 10:eaaj2005. https ://doi.org/10.1126/scisi gnal.aaj20 05
 161. Lundberg E, Brismar H, Gräslund T (2009) Selection and charac-
terization of  Affibody® ligands to the transcription factor c-Jun. 
Biotechnol Appl Biochem 52:17. https ://doi.org/10.1042/BA200 
70178 
 162. Lindgren J, Wahlström A, Danielsson J et al (2010) N-terminal 
engineering of amyloid-β-binding Affibody molecules yields 
improved chemical synthesis and higher binding affinity. Protein 
Sci 19:2319–2329. https ://doi.org/10.1002/pro.511
 163. Grönwall C, Jonsson A, Lindström S et al (2007) Selection 
and characterization of Affibody ligands binding to Alzheimer 
amyloid β peptides. J Biotechnol 128:162–183. https ://doi.
org/10.1016/J.JBIOT EC.2006.09.013
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
